Measurement of Myofilament-Localized Calcium Dynamics in Adult Cardiomyocytes and the Effect of Hypertrophic Cardiomyopathy Mutations.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30732532.
- Also identified by DOI 10.1161/CIRCRESAHA.118.314600 and PMC identifier 6485313.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Subcellular Ca<sup>2+</sup> indicators have yet to be developed for the myofilament where disease mutation or small molecules may alter contractility through myofilament Ca<sup>2+</sup> sensitivity. Here, we develop and characterize genetically encoded Ca<sup>2+</sup> indicators restricted to the myofilament to directly visualize Ca<sup>2+</sup> changes in the sarcomere. To produce and validate myofilament-restricted Ca<sup>2+</sup> imaging probes in an adenoviral transduction adult cardiomyocyte model using drugs that alter myofilament function (MYK-461, omecamtiv mecarbil, and levosimendan) or following cotransduction of 2 established hypertrophic cardiomyopathy disease-causing mutants (cTnT [Troponin T] R92Q and cTnI [Troponin I] R145G) that alter myofilament Ca<sup>2+</sup> handling. When expressed in adult ventricular cardiomyocytes RGECO-TnT (Troponin T)/TnI (Troponin I) sensors localize correctly to the sarcomere without contractile impairment. Both sensors report cyclical changes in fluorescence in paced cardiomyocytes with reduced Ca<sup>2+</sup> on and increased Ca<sup>2+</sup> off rates compared with unconjugated RGECO. RGECO-TnT/TnI revealed changes to localized Ca<sup>2+</sup> handling conferred by MYK-461 and levosimendan, including an increase in Ca<sup>2+</sup> binding rates with both levosimendan and MYK-461 not detected by an unrestricted protein sensor. Coadenoviral transduction of RGECO-TnT/TnI with hypertrophic cardiomyopathy causing thin filament mutants showed that the mutations increase myofilament [Ca<sup>2+</sup>] in systole, lengthen time to peak systolic [Ca<sup>2+</sup>], and delay [Ca<sup>2+</sup>] release. This contrasts with the effect of the same mutations on cytoplasmic Ca<sup>2+</sup>, when measured using unrestricted RGECO where changes to peak systolic Ca<sup>2+</sup> are inconsistent between the 2 mutations. These data contrast with previous findings using chemical dyes that show no alteration of [Ca<sup>2+</sup>] transient amplitude or time to peak Ca<sup>2+</sup>. RGECO-TnT/TnI are functionally equivalent. They visualize Ca<sup>2+</sup> within the myofilament and reveal unrecognized aspects of small molecule and disease-associated mutations in living cells.
Medical subject headings
- Calcium
- Cardiomyopathy, Hypertrophic
- Mutation
- Myocytes, Cardiac
- Myofibrils
- Sarcomeres